|
|
ASTRAZENECA (LON:AZN)
UK Pharmaceuticals & Biotechnology
|
|
Stock Of The Month
FEB 2026 - ISSUE #005
|
|
|
|
Stock Of The Month
|
|
FEB 2026 - ISSUE #005
|
|
ASTRAZENECA (LON:AZN)
|
|
UK Pharmaceuticals & Biotechnology
|
|
|
Executive Summary:
- The Story: AstraZeneca's oncology-led
pipeline has delivered exceptional 3-year growth: 13.1% revenue CAGR and 251.6% net
income CAGR, with a deep late-stage pipeline across oncology, rare disease, and
immunology
- Valuation: P/E of 29.3x looks
demanding, but a PEG of 0.96 suggests the stock is fairly priced relative to its
growth rate
- Catalysts: Multiple Phase III readouts
in 2026; continued oncology franchise expansion; potential new blockbusters from ADC
platform
- Key Risk: Patent cliffs on key drugs,
China regulatory risk following recent probes, and 28.5% annualized volatility
|
|
Openbook Risk/Reward Matrix
|
Reward
Score →
|
|
RISK
→
|
CAUTIOUS
Low Reward
· Low Risk
|
SWEET SPOT
High
Reward · Low Risk
AZN
|
|
AVOID
Low Reward
· High Risk
|
SPECULATIVE
High
Reward · High Risk
|
|
86
/100
Reward
|
33
/100
Risk
|
How We Score: Reward combines Growth (35%), Momentum (25%),
Profitability (20%), Valuation (15%), and Size (5%). Risk uses Solvency (35%),
Volatility (25%), and inverted versions of Growth, Margins, and Size.
|
|
5 YEAR SHARE PRICE HISTORY
From around £80 in 2021 to £130+ today. Steady upward trajectory driven by oncology
pipeline success.
|
1 Month
+2.5%
|
3 Month
+4.1%
|
6 Month
+24.7%
|
1 Year
+19.8%
|
5 Year
+55%
|
|
Reward Analysis
Our reward score analyses AZN's potential upside using 5 weighted factors.
|
86
/100
|
|
|
GROWTH (35% weight)
100/100 (Top
decile)
|
📈
|
🔍 What's Driving This: Key drivers include (1) Tagrisso, Imfinzi, and Enhertu
delivering
double-digit revenue growth; (2) Rare disease franchise (Alexion acquisition) fully integrated
and contributing; (3) FCF growing at 24.6% CAGR over 3 years.
Caution: The net income CAGR is inflated by a low 2021-22 base when AZN was investing
heavily in R&D and integrating Alexion. Growth is now normalising but remains strong.
|
Revenue CAGR (3yr)
13.1%
|
Net Income CAGR (3yr)
251.6%
|
FCF CAGR (3yr)
24.6%
|
70/100
Strong momentum. The +19.8% 12-month return coincides with
positive developments in the oncology pipeline. 6-month return of 24.7% shows
recent acceleration.
Note: 3m return (+4.1%) is modest. Watch for continued acceleration or mean reversion.
|
VALUATION (15%)
85/100
Valuation appears reasonable relative to growth. P/E of 29.3x is
demanding in
isolation, but PEG of 0.96 suggests the stock may be fairly priced relative to its
growth
rate (GARP).
P/E: 29.3x | EV/EBITDA: 10.8x | PEG: 0.96
|
PROFITABILITY (20%)
95/100
Excellent. Net margin of 13.0% with EBIT growth of 15.5%. ROE of
19.8% and ROA of 8.2% demonstrate strong capital efficiency. These metrics are
consistent with a quality compounder profile.
|
SIZE FACTOR (5%)
40/100
Large Cap (£166.9B). Typically more stable and liquid with
historically lower volatility than smaller peers. FTSE 100 constituent.
|
|
Risk Analysis
Our risk score assesses AZN's downside potential using 5 weighted factors.
|
33
/100
|
|
|
VOLATILITY (25% weight)
50/100 (Moderate)
|
📉
|
🔍 What This Means Practically: At 28.5% annualised volatility,
short-term price swings can be material. The -19.7% max
drawdown is within range of what large-cap growth stocks have historically experienced.
Individual risk tolerance will vary.
Context: Lower volatility than most growth stocks. AZN's large-cap status and
defensive pharma characteristics help dampen price swings.
|
Annualized Vol
28.5%
|
Max Drawdown
-19.7%
|
1-Year Return
+20.4%
|
|
FINANCIAL SOLVENCY (35%)
35/100
Low leverage risk. Net Debt/Equity of 0.60x is manageable. Interest
coverage of 6.2x provides financial flexibility. Net debt of £24.6B is covered by
strong cash generation.
|
OPERATIONAL QUALITY (30%)
20/100
Very robust. FCF margin of 13.5%, Cash ROA of 11.4%. Net margin of
13.0% with margin stability at 6.1%. Consistent cash generation buffers against
downturns.
|
SIZE RISK (10%)
20/100
Low existential risk. Large-cap (£166.9B) provides stability. Diversified
across oncology, rare disease, respiratory, and cardiovascular.
AZN vs Pharma Peers
How AstraZeneca stacks up against
Novo Nordisk & Roche
P/E Ratio (lower is cheaper)
Net Margin (higher is better)
12-Month Return (higher is better)
💡 Key Takeaway: AZN leads on momentum (+19.8% vs peers) at a lower P/E
than Novo Nordisk (29.3x vs 33.5x), suggesting a comparatively attractive entry point for
those considering pharma exposure.
|
Scenario Analysis
What could AZN be worth in 3 years? Based on current price of ~£130.
|
|
🟢 Bull Case
Pipeline delivers 3+ blockbusters from ADC platform. Revenue hits $80B target by
2030. P/E holds at 28x.
Target: £185 (+42%)
|
⚪ Base Case
Steady 10-12% revenue growth, patent cliffs managed through pipeline. P/E compresses
to 24x.
Target: £155 (+19%)
|
🔴 Bear Case
Key trial failures, China probe escalates, patent cliffs hit harder than expected.
P/E contracts to 18x.
Target: £90 (-31%)
|
These are illustrative scenarios, not forecasts. Actual outcomes depend on factors including
clinical trial results, regulatory decisions, and competitive dynamics.
|
⚠️ What Would Change Our View
- Net margin falls below 10% for 2 consecutive quarters
- Key Phase III trial failures in the oncology pipeline
- China regulatory risk escalates materially (revenue exposure ~13%)
- Patent cliff on Tagrisso without adequate pipeline replacement
|
What the Bears Say
Contrarian views and analyst concerns worth considering.
|
Berenberg • October 2025
"AZN's P/E of 29x is demanding for a pharma company. While pipeline is strong, valuations
already price in significant success from late-stage assets."
Patent Cliff Analysis • January 2026
"Tagrisso faces generic competition from 2028. At $5B+ in annual sales, this patent cliff
requires multiple pipeline wins to offset. History shows pharma companies often stumble
here."
China Risk • December 2025
"The Chinese regulatory investigation into AZN's operations adds uncertainty. China
represents ~13% of revenue, and any disruption could materially impact growth forecasts."
Margin Concerns • February 2026
"Net margins at 13% are below pharma peers like Novo Nordisk (34.8%). AZN's heavy R&D spend
is a double-edged sword — necessary for pipeline but compresses current profitability."
🔍 Our Take on the Bear Case
The valuation concerns are legitimate — at 30x earnings, AZN needs to keep executing.
However,
guidance has continued to beat expectations. The bears are right that easy gains may be
behind;
the question is whether operational momentum can sustain the multiple. Investors should
consider their own risk tolerance and position sizing accordingly.
|
The Investment Case
A balanced view of the bullish and bearish factors.
|
🟢 Bull Case
- Pipeline depth: 190+ projects
across oncology, rare disease, and immunology with multiple late-stage readouts
due in 2026
- Growth trajectory: 13.1% revenue
CAGR with $80B revenue target by 2030 is ambitious but supported by existing
franchise growth
- GARP credentials: PEG of 0.96
indicates growth at a reasonable price — relatively uncommon in large-cap pharma
- Defensive quality: Healthcare
spending has historically been more recession-resistant; AZN may offer growth
with some defensive characteristics
|
🔴 Bear Case
- Patent cliff risk: Tagrisso ($5B+
revenue) faces generic competition from 2028. Pipeline must deliver to offset
losses
- China exposure: ~13% of revenue
from China with ongoing regulatory probe adding uncertainty
- Margin gap: Net margin of 13% trails
Novo Nordisk's 34.8%, reflecting higher R&D intensity and integration costs
|
|
The Bottom Line
AZN exhibits characteristics of a quality compounder with genuine pipeline depth, rather than a
speculative pharma play. The 86/100 reward score and 33/100 risk score place it in the "Sweet Spot"
quadrant
of our matrix — relatively high upside potential with contained downside risk for a £167B FTSE 100
constituent.
Our observation: At a PEG of 0.96, AZN's valuation appears reasonable relative to
its growth rate. The
key risks remain the Tagrisso patent cliff and China exposure, though the pipeline depth may provide
a buffer. At 28.5% annualised volatility, AZN sits below many growth stocks on this measure. This is
not a recommendation to buy or sell.
Key catalysts to watch: Phase III readouts (H1 2026), Tagrisso replacement data,
China regulatory resolution, and progress toward $80B 2030 revenue target.
|
|
|
|
Coming Next Month
March Last Month in The Markets
|
Stay tuned...
|
|